Experimental drug aims to halt rare neurological decline

NCT ID NCT07681713

Not yet recruiting Disease control Sponsor: PTC Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether vatiquinone can slow the progression of Friedreich's ataxia, a rare genetic disorder that damages the nervous system and impairs movement. About 120 adults with moderate symptoms will take the drug for 24 months. Researchers will measure changes in movement, balance, and daily activities to see if the treatment preserves function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vatiquinone
What this could lead to: If successful, vatiquinone could become the first treatment to slow the progression of Friedreich's ataxia, preserving mobility and daily function for longer.
What could go wrong: This is a Phase 3 trial, but results may not show a clear benefit. The drug may cause side effects, and what works in this study may not help all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH'S ATAXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Friedreich ataxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRIEDREICH'S ATAXIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centre Hospitalier de l'Universite de Montreal CHUM

Montreal, Quebec, H2X 0A9, Canada
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Hospital Sant Joan de Deu

Barcelona, 08950, Spain
Hôpital Érasme (Hôpital Universitaire de Bruxelles)

Brussels, 1070, Belgium
Institut du Cerveau et de la Moelle Epinière

Paris, 75013, France
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Campinas

Campinas, São Paulo, 13083-888, Brazil
University of Iowa

Iowa City, Iowa, 52242, United States
University of South Florida

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.